Drug Trial Radar · NCT02566369
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Nov 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,208
Actual
Start
Nov 30, 2015
Primary completion
Nov 14, 2017
Study completion Nov 14, 2017
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Oct 2, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
CD5789 (trifarotene) 50μg/g creamDrug
CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
Placebo creamDrug
Placebo cream applied once daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator Global Assessment (IGA) Success Rate at Week 12Time frame: From Baseline to Week 12
Locations
124 sites in 5 countries. Site status is shown where the registry gives one.
Galderma Investigational Site (8258)
Mobile, Alabama
Galderma Investigational Site (# 8530)
Glendale, Arizona
Galderma Investigational Site (# 8511)
Phoenix, Arizona
Galderma Investigational Site (# 8009)
Hot Springs, Arkansas
Galderma Investigational Site (# 8355)
Rogers, Arkansas
Galderma Investigational Site (# 8456)
Beverly Hills, California
Galderma Investigational site (8578)
Cerritos, California
Galderma Investigational Site (# 8526)
Clovis, California
Galderma Investigational Site (8577)
Encinitas, California
Galderma Investigational Site (# 8224)
Fremont, California
Galderma Investigational Site (# 8509)
Fullerton, California
Galderma Investigational Site (# 8507)
Huntington Beach, California
Galderma Investigational Site (# 8425)
Newport Beach, California
Galderma Investigational Site (# 8052)
Oceanside, California
Galderma Investigational Site (# 8528)
Santa Ana, California
Galderma Investigational Site (# 8160)
Santa Monica, California
Galderma Investigational Site (# 8443)
Temecula, California
Galderma Investigational Site (8572)
Colorado Springs, Colorado
Galderma Investigational Site (# 8510)
Englewood, Colorado
Galderma Investigational Site (# 8370)
Boynton Beach, Florida
Galderma Investigational Site (# 8543)
Fort Lauderdale, Florida
Galderma Investigational Site (8143)
Miami, Florida
Galderma Investigational site (8259)
Miramar, Florida
Galderma Investigational Site (# 8522)
North Miami Beach, Florida
Galderma Investigational Site (# 8531)
Orange Park, Florida
Galderma Investigational Site (8502)
Orlando, Florida
Galderma Investigational Site (#8213)
Ormond Beach, Florida
Galderma Investigational Site (# 8529)
Sanford, Florida
Galderma Investigational Site (# 8455)
St. Petersburg, Florida
Galderma Investigational Site (# 8523)
Tampa, Florida
Galderma Investigational Site (# 8126)
West Palm Beach, Florida
Galderma Investigational Site (#8189)
Snellville, Georgia
Galderma Investigational Site (8582)
Idaho Falls, Idaho
Galderma Investigational Site (# 8367)
Arlington Heights, Illinois
Galderma Investigational Site (8191)
Chicago, Illinois
Galderma Investigational site (8571)
Darien, Illinois
Galderma Investigational Site (8575)
Oakbrook Terrace, Illinois
Galderma Investigational Site (# 8366)
Plainfield, Indiana
Galderma Investigational Site (# 8532)
Overland Park, Kansas
Galderma Investigational Site (# 8069)
Louisville, Kentucky
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.